Business Monitor International


France Pharmaceuticals & Healthcare Report

Published 19 February 2015

  • 133 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
France Pharmaceuticals & Healthcare Report

BMI View: France will remain among the largest pharmaceutical markets worldwide in the coming years, especially due to a large and aging population, as well as high per capita spending level s on medicines. However, several cost-containment measures will continue to exert downward pressure on market growth over a multi-year horizon. On the upside, current macroeconomic trends, including low oil and food prices, should be net positive for household consumption in France , posing upside risks to market forecasts in the medium - and long - term .

Headline Expenditure Projections

  • Pharmaceuticals: EUR33.06bn (USD44.29bn) in 2014 to EUR32.43bn (USD40.54bn) in 2015; -1.9% in local currency terms and -8.5% in US dollar terms. Forecast in line with last quarter.

  • Healthcare: EUR252.14bn (USD337.87bn) in 2014 to EUR259.42bn (USD324.27bn) in 2015; +2.9% in local currency terms and -4.0% in US dollar terms. Forecast in line with last quarter.

Risk/Reward Index

In Q215, France maintains an overall Risk/Reward Index (RRI) score of 71.7 out of 100. This means that France stands as the fourth most attractive market to pharmaceutical investors out of 15 markets in Western Europe. France's score is driven by the large multi-billion dollar drug market (market expenditure score of 16.0 out of 20), and large pensionable population (pensionable population score of 8.0 out of 8), but dragged down by poor market expansion (sector value growth score of 0.0 out of 12).

Key Trends And Developments

  • In January 2015, Roche agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France. Trophos' proprietary screening platform generated olesoxime (TRO19622), which is being developed for spinal muscular atrophy, a rare and debilitating genetic neuromuscular disease commonly diagnosed in children. Under the terms of the agreement, Trophos's shareholders will receive an upfront cash payment of EUR120mn, plus additional contingent payments of up to...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (France 2010-2018)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (France 2010-2018)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (France 2010-2018)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (France 2010-2018)
20
Prescription Drug Market Forecast
21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (France 2010-2018)
22
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (France 2010-2018)
23
France Generic Drug Market Forecast
24
Table: Generics Drug Market Indicators, Historical Data And Forecasts (France 2010-2018)
28
OTC Medicine Market Forecast
29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (France 2010-2018)
31
Pharmaceutical Trade Forecast
32
Table: Pharmaceutical Trade Data And Forecasts (France 2012-2018)
33
Table: Pharmaceutical Trade Data And Forecasts local currency (France 2012-2018)
34
Other Healthcare Data
34
Key Risks To BMI's Forecast Scenario
34
Macroeconomic Forecasts
36
Economic Analysis
36
Macro Outlook
36
Real GDP By Expenditure Breakdown
37
Risks To Outlook
40
Table: France - Economic Activity
41
Industry Risk Reward Ratings
42
Western Europe Risk/Reward Ratings
42
France Risk/Reward Ratings
47
Rewards
47
Risks
47
Market Overview
49
Industry Trends And Developments
50
Epidemiology
50
Prescription Drugs
51
Healthcare Financing
52
Public Hospitals
54
Table: Hospital Activity, 2005-2009
55
Table: Hospital Activity in Short-Stay Units, 2009
56
Table: Diagnostic & Therapeutic Procedures Performed in Public & Private Hospitals, 2009
57
Table: Regional Ranking Of Projected Physicians, 2017
59
Table: Projected Physicians, 2012-2017
59
Table: Medical Personnel, 2005-2010
60
Generic Drugs
60
Research & Development
61
Biotechnology
63
Clinical Trials
66
Regulatory Development
68
Intellectual Property Issues
70
Pricing & Reimbursement
71
Table: France Reimbursement Categories
71
Biosimilars
74
OTC Medicines
79
Competitive Landscape
80
Pharmaceutical Sector
80
Foreign Industry
82
Pharmaceutical Distribution
83
Pharmaceutical Retail Sector
84
Company Profile
86
Sanofi
86
Servier
96
Ipsen
101
Pfizer
106
GlaxoSmithKline
109
Novartis
112
Merck & Co
115
Demographic Forecast
117
Table: France's Population By Age Group, 1990-2020 ('000)
118
Table: France's Population By Age Group, 1990-2020 (% of total)
119
Table: France's Key Population Ratios, 1990-2020
120
Table: France's Rural And Urban Population, 1990-2020
120
Glossary
121
Methodology
123
Pharmaceutical Expenditure Forecast Model
123
Healthcare Expenditure Forecast Model
123
Notes On Methodology
124
Risk/Reward Ratings Methodology
125
Ratings Overview
126
Table: Pharmaceutical Risk/Reward Ratings Indicators
126
Indicator Weightings
127

The France Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's France Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the France pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for France, to test other views - a key input for successful budgeting and strategic business planning in the French pharmaceutical and healthcare market.
  • Target business opportunities and risks in the French pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in France.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc